38 results about "Peripheral blood lymphocyte" patented technology

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.

The application discloses an application of baicalin in treating coronavirus infectious diseases. The new application of baicalin is verified through in-vitro cell tests and mouse tests infected with human coronavirus HCoV-229E, the technical scheme is novel, and a curative effect test of baicalin in treating pneumonia caused by HCoV-229E virus infection is carried out, and the results show that baicalin has a certain inhibitory effect on HCoV-229E infected cells in vitro; baicalin shows good drug efficacy in lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, can reduce the virus load of lung tissue of pneumonia mice infected with HCoV-229E virus, increase the proportion of peripheral blood lymphocytes of mice, and reduce the content of IL-2, IL-10, TNF-alpha and IFN-beta in lung tissue of mice.

The invention provides a method for detecting insulin sensitivity, which comprises the following steps: (1) transfecting a cell to be detected by using a GLUT4myc cDNA plasmid: transfecting the cell to be detected by using the GLUT4myc cDNA plasmid, so that the cell stably expresses GLUT4myc; (2) measuring the endocytosis rate of the GLUT4myc: performing endocytosis stimulation to enable the GLUT4myc combined with the anti-myc antibody to be endocytosed, and regularly detecting the amount of the GLUT4myc combined with the anti-myc antibody remained on the surface of the cell; (3) measuring the GLUT4myc exocytosis rate: performing exocytosis stimulation to enable the GLUT4myc combined with the anti-myc antibody in the cell to exocytosis, and regularly detecting the translocation amount of the GLUT4myc combined with the anti-myc antibody in the cell to the surface of the cell; (4) calculating the difference value between the GLUT4myc exocytosis rate and the GLUT4myc endocytosis rate, and calculating the insulin sensitivity according to the difference value; the insulin sensitivity evaluation method has the beneficial effects that the insulin sensitivity is evaluated by detecting the exocytosis and endocytosis rates of fat cells, muscle cells or peripheral blood lymphocytes GLUT4, so that early-stage diabetic patients can be identified, and the pathogenesis of diabetes mellitus can be researched.

This invention discloses a T-cell training method based on tumor organ-on-a-chip. The method includes: preparing an organ-on-a-chip with a micropillar array and a biomimetic fishbone structure; introducing primary tumor cells from a patient into the chip, causing them to spontaneously form uniform three-dimensional tumor spheroids; dynamically pumping pre-activated peripheral blood lymphocytes from the same patient into the chip and co-culturing them with the tumor spheroids; collecting the co-cultured lymphocytes and repeating the co-culture process multiple times to obtain a lymphocyte population with enhanced anti-tumor activity. This invention utilizes organ-on-a-chip technology to highly simulate the dynamic tumor immune microenvironment in vivo. Through multiple cycles of "training," it effectively activates and expands tumor-specific T cells, avoiding immune exhaustion, and providing a highly efficient and controllable new platform for personalized immunotherapy of solid tumors.

According to the method and device for predicting recurrence after HCC local treatment, multi-time-point peripheral blood lymphocyte subgroups are utilized, an integrated lymphocyte subgroup index is established through related factor screening and model optimization, and clinical information is assisted to establish an immune-clinical combined model to evaluate microwave ablation prognosis of liver cancer patients, so that liver cancer MWA postoperative recurrence and death risks are predicted in the early stage; the dynamic change of the lymphatic subgroup of the patient is longitudinally evaluated for multiple times through the verification queue to serve as input information to optimize the model, and guidance is provided for MWA preoperative planning and prognosis dynamic monitoring. The method comprises the following steps: (1) screening and constructing an accurate prediction model based on a circulating lymphatic subgroup; (2) explaining immune level change characteristics of the patient after ablation through the model, and performing prognosis risk assessment; and (3) verifying the efficacy of the post-treatment lymphatic subgroup dynamic monitoring and prediction model and re-optimizing the model.

Provided herein are methods of making tumor reactive peripheral blood lymphocytes (trPBLs) using PBMCs obtained from a patient. The method comprises enriching trPBLs from PBMCs using markers that are expressed or secreted by the trPBLs, such as 4- IBB, CD103, CXCL13, IFN-y, CXCR6, CD200, HLA-DR, CD69, PD-1, CD39, CD38, CD49a, etc. Further provided are use of the trPBLs or pharmaceutical compositions thereof for the treatment of cancers.

The invention discloses a screening method and application of a shark-derived anti-idiotypic nano antibody, and belongs to the technical field of biological pharmacy and vaccines. The screening method comprises the following steps: immunizing adult shark by using a target pathogen specific antigen, collecting peripheral blood, separating lymphocytes, extracting RNA (Ribonucleic Acid), carrying out reverse transcription to synthesize cDNA (Complementary Deoxyribonucleic Acid), amplifying a nano antibody variable region fragment of a shark IgNAR (Immunoglobulin Nucleic Acid Receptor) gene, and constructing a phage display gene bank of which the storage capacity is greater than or equal to 1 * 10 < 8 > CFU and the recombination rate is greater than or equal to 85%; a variable region of a target pathogen specific antibody is taken as a target, specific bacteriophage is enriched through 3-4 rounds of gradient washing and elutriation (Tween-20 concentration and washing time are gradually improved), and the shark source anti-idiotypic nano antibody with high affinity and high purity (greater than or equal to 95%) is obtained by combining ELISA screening positive clone, gene sequencing de-weighting and SPR detection (combining dissociation constant KDlt, 1 * 10 <-7 > mol / L).

Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and / or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.

The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and / or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and / or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.

The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and / or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and / or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.

The invention discloses application of a detection reagent in malignant differentiation detection of Carbosi sarcoma, and belongs to the technical field of biological medicine. Aiming at the problem of insufficient specificity of a malignant differentiation marker of Carbosi sarcoma in the prior art, the invention provides application of a detection reagent in detection of the malignant differentiation of Carbosi sarcoma, and the detection reagent can simultaneously detect two biomarkers, namely CXCL12 and VWF, and is used for identifying endothelial cell malignant differentiation subgroups in tissue focuses of Carbosi sarcoma. By detecting the expression of CXCL12 and VWF in a tested sample, the endothelial cell malignant differentiation subgroup can be stably identified, and meanwhile, the expression level of CXCL12 can be used as an indicator of disease progression: the higher the expression level of CXCL12 is, the higher the lesion progression degree is, the higher the risk is, and the expression level is also positively correlated with the counting of peripheral blood lymphocytes. According to the invention, high-specificity recognition and standardized reading of the endothelial cell malignant differentiation subgroups are realized.

According to the present disclosure, optimization of treatment for a rejection reaction by immune tolerance induction is provided.According to the present disclosure, there is provided a method for evaluating quality of a medicament for achieving immune tolerance, which is administered to a patient who has undergone living-donor liver transplantation, the method including: (a) a step of mixing and culturing peripheral blood lymphocytes collected from a patient before the living-donor liver transplantation and peripheral blood lymphocytes collected from a donor of the living-donor liver transplantation; (b) a step of mixing and culturing peripheral blood lymphocytes collected from the patient before the living-donor liver transplantation, peripheral blood lymphocytes collected from the donor of the living-donor liver transplantation, and the medicament for achieving immune tolerance in the patient; and (c) a step of measuring cytokine production in steps (a) and (b), in which in a case where the cytokine production in step (b) has changed compared to step (a), the medicament is considered to be a medicament for immune tolerance therapy.

The invention relates to the technical field of biological pharmacy, in particular to a nano antibody with high affinity with a human DR3 extracellular domain. The method comprises the following steps: immunizing alpaca by using a DR3 extracellular domain of an insect expression system, separating peripheral blood lymphocytes, performing total RNA extraction, performing reverse transcription, amplifying a nano-antibody sequence, and finally separating to obtain a nano-antibody named as H10. The SPR (Surface Plasmon Resonance) result shows that the nano antibody can be combined with the extracellular domain of human DR3 with high affinity, and the nano antibody provided by the invention is expected to provide an experimental factual basis for the treatment thought of DR3-related diseases.

The present application relates to the technical field of biopharmaceuticals, and particularly relates to a kind of nanobody with high affinity to human DR3 extracellular domain.The present application immunizes alpaca with the extracellular domain of DR3 of insect expression system, separates peripheral blood lymphocyte to carry out total RNA extraction, reverses transcription and amplifies nanobody sequence, finally separates and obtains nanobody, and is named H10.SPR result shows that the nanobody shows high affinity binding to human DR3 extracellular domain, and the nanobody provided by the present application has the potential to provide experimental fact basis for the treatment idea of DR3 related diseases.

The application provides an HE chromatin control product, a preparation method and application thereof, including a control slide, the control slide includes a first smear area and a second smear area, the first smear area and the second smear area are respectively arranged in different areas of the control slide, the first smear area is uniformly coated with mammalian peripheral blood mature red blood cells, and the second smear area is uniformly coated with mammalian peripheral blood lymphocytes. The HE chromatin control product provided by the application includes the combination of the mature red blood cell first smear area and the lymphocyte second smear area, can respectively and specifically reflect the staining effect of cytoplasm and nucleus in HE staining, realizes independent quality control of nucleus and plasma, the blood cell source is uniform, the difference of human body structure can be eliminated, batch uniformity and stability can be ensured, quantitative detection can be realized through a microspectrophotometer, objective and quantitative staining quality can be realized, the subjective and standardized difficulty problem of traditional quality control can be solved, and the accuracy and consistency of pathological quality control are improved.

The invention belongs to the field of biological medicine, and discloses a culture method and application of an organoid. The culture method is easy to operate and high in success rate. The organoid constructed by the method can be used for constructing an in-vitro organoid and peripheral blood lymphocyte co-culture system to evaluate the curative effect of tumor immunotherapy, the co-culture system predicts that AUC which is possibly invalid in immunotherapy is 0.82 (95% CI, 0.71-0.93), the sensitivity can reach 90.90%, the specificity is 73.50%, the positive predictive value is 77.42%, and the negative predictive value is 88.98%, which are obviously higher than PD-L1 (the sensitivity is 63.60%; the specificity is 37.20%), a new screening index is provided for determination of a precise immunotherapy scheme, and the treatment effect of a patient is improved.

This invention discloses a shark-derived nanobody targeting the SARS-CoV-2 RBD protein and its applications. The nanobody's nucleotide sequence is shown in SEQ ID NO: 1, and its amino acid sequence is shown in SEQ ID NO: 5. Preparation involves immunizing a striped bamboo shark with the RBD protein, extracting total RNA from peripheral blood lymphocytes and reverse transcribing it into cDNA. The amplified VNAR fragment is then seamlessly ligated with amplified pR2 phage particles, transformed into TG1 competent cells, and a phage antibody library is constructed. SARS-CoV-2 RBD protein-specific nanobody sequences are screened from the library and recombinantly expressed to obtain the targeted shark-derived nanobody. The nanobody of this invention has a small molecular weight, allowing for the detection of the SARS-CoV-2 RBD antigen using paired nanobodies. It can be applied to immunoblotting, enzyme-linked immunosorbent assays (ELISA), and COVID-19 pharmaceutical applications related to the SARS-CoV-2 RBD protein.

The invention discloses application of radix trichosanthis polysaccharide to preparation of a medicine for regulating immunity and inhibiting postoperative recurrence of colorectal cancer. The radix trichosanthis polysaccharide is found to be capable of promoting M2 phenotype macrophages to be polarized to M1 phenotype, and has an immunoregulation function; meanwhile, proliferation of peripheral blood lymphocytes and spleen lymphocytes is promoted, the proportion of CD4 +, CD8 + and NK cells is increased, and the effect of enhancing immunity is achieved. Furthermore, the hydrogel CMOT prepared by taking the radix trichosanthis polysaccharide as the raw material has good biocompatibility in vitro and in vivo and has the qualified characteristic of hydrogel, and the CMOT hydrogel is found to have the effect of inhibiting the recurrence of the colorectal cancer when being applied to the resection part of the mouse colorectal cancer operation. Therefore, the radix trichosanthis polysaccharide hydrogel has the potential of becoming a postoperative wound dressing after cancer resection.

The invention relates to the technical field of biological pharmacy, in particular to a DR3 extracellular domain targeting nano antibody. The method comprises the following steps: immunizing alpaca by using a DR3 extracellular domain of an insect expression system, separating peripheral blood lymphocytes, carrying out total RNA extraction, carrying out reverse transcription, amplifying a nano-antibody sequence, and finally separating to obtain the nano-antibody named as A6. The SPR (Surface Plasmon Resonance) result shows that the nano antibody can be combined with the extracellular domain of human DR3 with high affinity, and the nano antibody provided by the invention is expected to provide an experimental factual basis for the treatment thought of DR3-related diseases.

The present application relates to the technical field of biopharmaceuticals, and particularly relates to a nano-antibody targeting DR3 extracellular domain. The present application immunizes a llama with DR3 extracellular domain of an insect expression system, extracts total RNA from peripheral blood lymphocytes, reversely transcribes and amplifies nano-antibody sequences, and finally separates and obtains a nano-antibody, named A6. SPR results show that the nano-antibody exhibits high affinity binding with human DR3 extracellular domain, and the nano-antibody provided by the present application is expected to provide experimental fact basis for the treatment idea of DR3 related diseases.

The invention belongs to the field of medicine, and particularly relates to a marker for evaluating the severity and clinical outcome of systemic lupus erythematosus disease, and the systemic lupus erythematosus disease is lupus nephritis, namely LN; the marker comprises a first combined marker, and the first combined marker is the number of CD3 + TIM3 + T lymphocytes or the proportion of CD3 + TIM3 + T lymphocytes in the total amount of peripheral blood T lymphocytes of a patient; the marker can also be one or more of a first combined marker CD3 + TIM3 + T lymphocyte, a second combined marker CD4 + CD25 + CD127-T lymphocyte, a third combined marker CD3 + LAG3 + T lymphocyte and a fourth combined marker CD3 + CTLA4 + T lymphocyte. The marker for evaluating the severity of the lupus nephritis disease is more accurate than an SLE traditional index, and the marker can be used for evaluating the clinical outcome of the lupus nephritis.

The invention relates to the field of biological medicines, and provides application of Amuc1409 protein in prevention and treatment of acute pancreatitis. When the Amuc1409 protein is used for preventing or treating acute pancreatitis, the Amuc1409 protein plays a role through at least one of the following ways: (1) reducing the amylase concentration in serum; (2) relieving acinus cell injury and inflammatory cell infiltration; (3) reducing transcription of inflammatory cytokines in pancreas; and (4) increasing the proportion of regulatory T cells in peripheral blood lymphocytes. The invention discovers and verifies the effect of Ackermann secretory protein Amuc1409 in the aspect of preventing and treating acute pancreatitis for the first time, and the prevention and treatment effect is superior to that of Ackermann membrane protein Amuc1100.

This invention belongs to the field of nanobody technology, and relates to an anti-CD63 protein nanobody, its preparation method, and its application. The amino acid sequence of the nanobody is shown in SEQ ID NO.1. This invention utilizes CD63 protein as an immunogen to immunize alpacas, extracts total RNA from their peripheral blood lymphocytes, amplifies the VHH fragment via reverse transcription and two rounds of nested PCR, digests and ligates the VHH fragment with the pComb3XSS plasmid using enzymes, and transforms it into TG1 competent cells. Using phage display technology, after three rounds of screening, an anti-CD63 protein nanobody was successfully screened. This nanobody exhibits high specificity and good binding affinity, providing a new direction for the identification, enrichment, and purification of extracellular vesicles or exosomes, and for disease (such as tumor) diagnosis and targeted drug delivery.

The invention discloses a biomarker, a kit and a scoring system for autism detection, and belongs to the technical field of biological medicines. According to the application, mRNA expression conditions of AKR1C3, HMOX1 and PEX6 in peripheral blood lymphocytes are detected, so that the expression level of AKR1C3 in autism patients is obviously higher than that of a normal group, the expression level of HMOX1 in autism patients is obviously lower than that of the normal group, and the expression level of PEX6 in autism patients is obviously higher than that of the normal group. Therefore, the invention develops a gene detection kit which is used for detecting mRNA level changes of peripheral blood lymphocytes AKR1C3, HMOX1 and PEX6, and an autism scoring system is designed according to expression conditions of the peripheral blood lymphocytes AKR1C3, HMOX1 and PEX6. The kit and the scoring system are more accurate and reliable in detection result, good in stability and repeatability, capable of reflecting autism conditions and capable of being used for early warning of autism diagnosis.

The invention discloses a pharmaceutical composition containing Wanshu capsules as an active ingredient and used for repairing immune organs. The Wanchu capsule provided by the invention can obviously increase the proportion of peripheral blood lymphocytes.

The present invention provides a rabbit-derived Fab antibody against CD30, its preparation method and application. In the present invention, human CD30 protein is recombinantly expressed in vitro, and rabbits are immunized three times with the CD30 protein. Then, peripheral blood lymphocytes are isolated and their total RNA is extracted, which is reverse transcribed into cDNA. Using this cDNA as a template, the Fab sequence is amplified with specific primers. Furthermore, through yeast display technology, a Fab antibody capable of binding to the CD30 protein is screened, and the Fab sequence is combined with the rabbit Fc domain to obtain a fusion protein with high purity. The strong activity of this Fab antibody with CD30 and its specific binding ability to tumor cells are verified at the cellular level.

The invention provides an application of a plantain fruit extract in immunoregulation, in particular to an application of the plantain fruit extract in regulation of human peripheral blood lymphocyte immunophenotype. Through a multi-target immune regulation mechanism (B cell inhibition, NK function activation and Th polarization), the extract significantly improves the phenotypic imbalance of peripheral blood lymphocytes, and especially shows an outstanding prevention value in people in an immune critical state. The invention provides a new theoretical basis and transformation direction for the development of plant-derived immunomodulators.

The invention belongs to the technical field of nano antibodies, and particularly relates to a BCMA nano antibody and application thereof. The preparation method comprises the following steps: immunizing alpaca by using BCMA recombinant protein, separating peripheral blood lymphocytes, constructing a gene library, and screening an anti-BCMA nano antibody from the library. The nano antibody provided by the invention has unique complementary determining regions 1, 2 and 3, and the antibody has high specific binding capacity to a BCMA antigen. According to the human FC fusion antibody constructed by the nano antibody, the nano antibody has ideal capability of combining multiple myeloma (MM) cells and inducing T cells to kill the MM cells. The compound can be applied independently or in combination with other MM drugs, and is used for preparing MM therapeutic drugs. According to the technical scheme, the technical problems that in the prior art, a nano antibody aiming at BCMA is lacked and the variety of drugs for treating multiple myeloma is limited can be solved, and the nano antibody has ideal application and popularization prospects.

The invention discloses a human mesenchymal stem cell preparation activated by specific immune pretreatment and application thereof, and the application is characterized in that human mesenchymal stem cells (hAMSCs) and autologous human peripheral blood lymphocytes are co-cultured and pretreated according to a specific ratio (such as 100: 1), and then are applied to a knee osteoarthritis model through intra-articular injection. The synergistic treatment effect which is obviously superior to that of the unpretreated hAMSCs can be generated; the Co-hAMSCs show a unique in-vivo action mode, the survival time of the Co-hAMSCs at the local part of the joint is shorter than that of common hAMSCs, but the Co-hAMSCs can quickly relieve pain in the early treatment stage, improve the joint function and lower local inflammation; the cartilage repair and regeneration can be more effectively promoted for a long time, and the specific expression is as follows: the cartilage histological score is obviously improved, the content of cartilage matrix glycosaminoglycans (especially middle and deep layers) is increased, and the repaired tissue is guided to be transformed to a hyaline cartilage sample phenotype with high expression of type II collagen and low expression of type I collagen, so that the cartilage repair and regeneration can be more effectively promoted. And inflammatory factor balance of local joints and the whole body can be synchronously adjusted.

The application discloses a single-domain antibody of decapod iridovirus 1 and a preparation method and application thereof, amino acid sequences of the single-domain antibody are shown in SEQ ID NO:1 or SEQ ID NO:2, and gene sequences are shown in SEQ ID NO:3 or SEQ ID NO:4; meanwhile, the application also provides a preparation method of the single-domain antibody of decapod iridovirus 1, adult healthy striped bonnet sharks are taken as immunization objects, and immunization is carried out by adopting DIV1 as an antigen; total RNA is extracted by separating peripheral blood lymphocytes of the immunized striped bonnet shark, and then the total RNA is reversely transcribed into cDNA; the cDNA is taken as a template, a vNAR fragment of the striped bonnet shark is amplified, and the vNAR fragment is connected with a carrier to construct a phage library; positive clones recognizing the DIV1 are selected from the phage library; an expression vector is constructed, the single-domain antibody of the DIV1 is induced to express, and finally the single-domain antibody of the decapod iridovirus 1 is obtained; and the single-domain antibody of the decapod iridovirus 1 is used for detecting the decapod iridovirus 1.